LON:EVG - Evgen Pharma Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 5.86
▼ -0.091 (-1.53%)

This chart shows the closing price for EVG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evgen Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVG

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Evgen Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 5.86.

This chart shows the closing price for EVG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Evgen Pharma. This rating has held steady since December 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/15/2020FinnCapReiterated RatingCorporate
2/13/2020FinnCapReiterated RatingCorporate
12/17/2019FinnCapReiterated RatingCorporate
12/5/2019FinnCapReiterated RatingCorporate
11/11/2019FinnCapReiterated RatingCorporate
9/23/2019FinnCapReiterated RatingCorporate
8/7/2019FinnCapReiterated RatingCorporate
6/13/2019FinnCapReiterated RatingCorporate
4/18/2019FinnCapReiterated RatingCorporateGBX 45 ➝ GBX 35
4/2/2019FinnCapInitiated CoverageCorporateGBX 45
12/12/2018Northland SecuritiesReiterated RatingBuy
12/4/2018Northland SecuritiesReiterated RatingBuy
10/18/2018Northland SecuritiesReiterated RatingBuy
9/11/2018Northland SecuritiesReiterated RatingBuyGBX 113
7/27/2018Northland SecuritiesReiterated RatingBuyGBX 113
7/25/2018Northland SecuritiesReiterated RatingBuy
6/11/2018Northland SecuritiesReiterated RatingBuyGBX 113
5/4/2018Northland SecuritiesReiterated RatingBuyGBX 113
4/24/2018Northland SecuritiesReiterated RatingBuyGBX 113
3/20/2018Northland SecuritiesReiterated RatingBuy
3/5/2018Northland SecuritiesReiterated RatingCorporate
1/15/2018Northland SecuritiesReiterated RatingBuy
12/15/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
10/5/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
10/4/2017Northland SecuritiesReiterated RatingBuyGBX 97
8/3/2017Northland SecuritiesReiterated RatingBuyGBX 97
7/26/2017Northland SecuritiesReiterated RatingBuyGBX 97
6/13/2017Northland SecuritiesReiterated RatingBuyGBX 97
6/1/2017Northland SecuritiesReiterated RatingBuyGBX 97
3/29/2017Northland SecuritiesReiterated RatingBuyGBX 97
2/13/2017Northland SecuritiesReiterated RatingBuyGBX 97
1/18/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
1/13/2017Northland SecuritiesReiterated RatingBuyGBX 97
1/12/2017Beaufort SecuritiesReiterated RatingSpeculative Buy
12/5/2016Northland SecuritiesReiterated RatingBuyGBX 97
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
7/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2021

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Evgen Pharma logo
Evgen Pharma plc, a clinical stage drug development company, engages in developing sulforaphane based medicines for the treatment of multiple diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of metastatic breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer, autism, non-alcoholic steatohepatitis, and chronic kidney diseases. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.
Read More

Today's Range

Now: GBX 5.86
Low: 5.86
High: 5.99

50 Day Range

MA: GBX 5.77
Low: 4.90
High: 7.15

52 Week Range

Now: GBX 5.86
Low: 4.22
High: 15.50

Volume

26,277 shs

Average Volume

1,889,721 shs

Market Capitalization

£16.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Evgen Pharma?

The following Wall Street sell-side analysts have issued stock ratings on Evgen Pharma in the last year:
View the latest analyst ratings for EVG.

What is the current price target for Evgen Pharma?

0 Wall Street analysts have set twelve-month price targets for Evgen Pharma in the last year. has the lowest price target set, forecasting a price of £100,000 for Evgen Pharma in the next year.
View the latest price targets for EVG.

What is the current consensus analyst rating for Evgen Pharma?

Evgen Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EVG.

How do I contact Evgen Pharma's investor relations team?

Evgen Pharma's physical mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company's listed phone number is +44-151-7053532. The official website for Evgen Pharma is evgen.com.